'On consolidated basis

Quarter ended March 2025 compared with Quarter ended March 2024.

Net sales (including other operating income) of Aurobindo Pharma has increased 10.58% to Rs 8382.12 crore.  Operating profit margin has declined from 22.07% to 21.38%, leading to 7.12% rise in operating profit to Rs 1,791.92 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 33.18% to 33.37%.   Purchase of finished goods cost fell from 9.90% to 7.58%.   Employee cost increased from 12.93% to 13.86%.   Other expenses rose from 22.92% to 23.83%.   

Other income fell 0.60% to Rs 134.81 crore.  PBIDT rose 6.54% to Rs 1926.73 crore.  Provision for interest rose 28.61% to Rs 115.02 crore.  Loan funds rose to Rs 8,262.87 crore as of 31 March 2025 from Rs 6,647.63 crore as of 31 March 2024.  Inventories rose to Rs 10,543.72 crore as of 3...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026